PMID- 33053214
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20220531
IS  - 1399-0012 (Electronic)
IS  - 0902-0063 (Linking)
VI  - 34
IP  - 12
DP  - 2020 Dec
TI  - The effect of human leukocyte antigen A1 and B35-Cw4 on sustained BK polyomavirus 
      DNAemia after renal transplantation.
PG  - e14110
LID - 10.1111/ctr.14110 [doi]
AB  - Human leukocyte antigen (HLA) class I presentation pathway plays a central role 
      in natural killer (NK) cell and cytotoxic T-cell activities against BK 
      polyomavirus (BKPyV) DNAemia. We determined the risk of sustained BKPyV DNAemia 
      in 175 consecutive renal transplant recipients considering the simultaneous 
      effect of donor/recipient HLA class I antigens and pre- or post-transplant 
      variables. Median (IQR) age was 53 (44-64) years, and 37% of patients were 
      female. 40 patients (22.9%) developed sustained BKPyV DNAemia [median (IQR) viral 
      load: 9740 (4350-17 125) copies/ml]. In the Cox proportional hazard analysis, 
      HLA-A1 (HR: 3.06, 95% CI: 1.51-6.17) and HLA-B35-Cw4 (HR: 4.63, 95% CI: 
      2.12-10.14) significantly increased the risk of sustained BKPyV DNAemia, while 2 
      HLA-C mismatches provided a marginally protective effect (HR: 0.32, 95% CI: 
      0.10-0.98). HLA-Cw4 is a ligand for NK cell inhibitory receptor, and HLA-B35 is 
      in strong linkage disequilibrium with the HLA-Cw4 allele. The association between 
      HLA-B35-Cw4 expression and sustained BKPyV DNAemia supports the important role of 
      cytotoxic T cells and NK cells that would normally control BKPyV activation 
      through engagement with immunoglobulin-like killer receptors (KIRs). Further 
      studies are required to investigate the effect of HLA-C alleles along with NK 
      cell activity against BKPyV DNAemia.
CI  - (c) 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd.
FAU - Hosseini-Moghaddam, Seyed M
AU  - Hosseini-Moghaddam SM
AUID- ORCID: 0000-0001-7979-2458
AD  - Division of Infectious Diseases, Department of Medicine, University Health 
      Network, University of Toronto, Toronto, ON, Canada.
AD  - Department of Epidemiology and Biostatistics, Western University, London, ON, 
      Canada.
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
FAU - Xu, Qingyong
AU  - Xu Q
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
AD  - Histocompatibility Laboratory, University of Pittsburgh Medical Center, 
      Pittsburgh, PA, USA.
FAU - Jevnikar, Anthony M
AU  - Jevnikar AM
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
FAU - House, Andrew A
AU  - House AA
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
FAU - Luke, Patrick
AU  - Luke P
AUID- ORCID: 0000-0002-9089-6933
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
FAU - Campigotto, Aaron
AU  - Campigotto A
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON, Canada.
FAU - Kum, Jina J Y
AU  - Kum JJY
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
AD  - Department of Pathology and Laboratory Medicine, London Health Sciences Centre, 
      Western University, London, ON, Canada.
FAU - Singh, Gagandeep
AU  - Singh G
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
FAU - Alharbi, Hajed
AU  - Alharbi H
AD  - Multiorgan Transplant Program, London Health Sciences Centre, Western University, 
      London, ON, Canada.
FAU - Speechley, Mark R
AU  - Speechley MR
AD  - Department of Epidemiology and Biostatistics, Western University, London, ON, 
      Canada.
LA  - eng
PT  - Journal Article
DEP - 20201028
PL  - Denmark
TA  - Clin Transplant
JT  - Clinical transplantation
JID - 8710240
RN  - 0 (HLA-A1 Antigen)
SB  - IM
MH  - Adult
MH  - *BK Virus/genetics
MH  - Female
MH  - HLA-A1 Antigen
MH  - Humans
MH  - *Kidney Transplantation/adverse effects
MH  - Male
MH  - Middle Aged
MH  - *Polyomavirus Infections/etiology
MH  - Transplant Recipients
OTO - NOTNLM
OT  - BKPy virus
OT  - kidney transplantation
OT  - polyomavirus
OT  - viremia
EDAT- 2020/10/15 06:00
MHDA- 2021/06/24 06:00
CRDT- 2020/10/14 18:00
PHST- 2020/07/02 00:00 [received]
PHST- 2020/10/01 00:00 [revised]
PHST- 2020/10/03 00:00 [accepted]
PHST- 2020/10/15 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/10/14 18:00 [entrez]
AID - 10.1111/ctr.14110 [doi]
PST - ppublish
SO  - Clin Transplant. 2020 Dec;34(12):e14110. doi: 10.1111/ctr.14110. Epub 2020 Oct 
      28.